🟢 Humacyte is trading 6% up in pre-market

Humacyte is trading at $0.46, up 6.06% in pre-market, with the catalyst uncertain.

• The October 16 close was $0.43.
• Humacyte’s October 15 release reported a 44% third-quarter increase in hospitals ordering Symvess, from 34 to 49; it does not establish the cause of this move.
• No clearly verified October 19 company-specific announcement explains the gain. Reported biotech-sector weakness also does not explain it.